95 related articles for article (PubMed ID: 19253368)
1. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation.
van den Broek GB; Wildeman M; Rasch CR; Armstrong N; Schuuring E; Begg AC; Looijenga LH; Scheper R; van der Wal JE; Menkema L; van Diest PJ; Balm AJ; van Velthuysen ML; van den Brekel MW
Int J Cancer; 2009 Jun; 124(11):2643-50. PubMed ID: 19253368
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F
Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
[TBL] [Abstract][Full Text] [Related]
6. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.
Moreno-Galindo C; Hermsen M; García-Pedrero JM; Fresno MF; Suárez C; Rodrigo JP
Oral Oncol; 2014 Feb; 50(2):128-34. PubMed ID: 24239278
[TBL] [Abstract][Full Text] [Related]
7. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.
Pavón MA; Parreño M; León X; Sancho FJ; Céspedes MV; Casanova I; Lopez-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Int J Cancer; 2008 Sep; 123(5):1068-79. PubMed ID: 18546291
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma.
Michaud WA; Nichols AC; Mroz EA; Faquin WC; Clark JR; Begum S; Westra WH; Wada H; Busse PM; Ellisen LW; Rocco JW
Clin Cancer Res; 2009 Mar; 15(5):1645-54. PubMed ID: 19240170
[TBL] [Abstract][Full Text] [Related]
9. High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
Chen YJ; Rau KM; Chien CY; Fang FM; Huang TL; Chiu TJ
Asian Pac J Cancer Prev; 2011; 12(3):649-55. PubMed ID: 21627359
[TBL] [Abstract][Full Text] [Related]
10. Use of multiple biological markers in radiotherapy-treated head and neck cancer.
Silva P; Slevin NJ; Sloan P; Valentine H; Ryder D; Price P; West CM; Homer JJ
J Laryngol Otol; 2010 Jun; 124(6):650-8. PubMed ID: 20388242
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Jonathan RA; Wijffels KI; Peeters W; de Wilde PC; Marres HA; Merkx MA; Oosterwijk E; van der Kogel AJ; Kaanders JH
Radiother Oncol; 2006 Jun; 79(3):288-97. PubMed ID: 16730088
[TBL] [Abstract][Full Text] [Related]
13. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ
Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.
Higuchi E; Oridate N; Homma A; Suzuki F; Atago Y; Nagahashi T; Furuta Y; Fukuda S
Head Neck; 2007 Oct; 29(10):940-7. PubMed ID: 17563903
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.
Yip HT; Chopra R; Chakrabarti R; Veena MS; Ramamurthy B; Srivatsan ES; Wang MB
Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):317-26. PubMed ID: 16549753
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
Wildeman MA; Gibcus JH; Hauptmann M; Begg AC; van Velthuysen ML; Hoebers FJ; Mastik MF; Schuuring E; van der Wal JE; van den Brekel MW
Laryngoscope; 2009 Feb; 119(2):316-22. PubMed ID: 19160427
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of basaloid squamous cell carcinoma in head and neck cancer.
Linton OR; Moore MG; Brigance JS; Gordon CA; Summerlin DJ; McDonald MW
JAMA Otolaryngol Head Neck Surg; 2013 Dec; 139(12):1306-11. PubMed ID: 24158536
[TBL] [Abstract][Full Text] [Related]
19. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review.
Swartz JE; Pothen AJ; Stegeman I; Willems SM; Grolman W
Cancer Med; 2015 Jul; 4(7):1101-16. PubMed ID: 25919147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
